Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer.

[1]  A. Partin,et al.  Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. , 2001, Urology.

[2]  D. Chan,et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. , 2000, The Journal of urology.

[3]  R W Veltri,et al.  Analysis of repeated biopsy results within 1 year after a noncancer diagnosis. , 2000, Urology.

[4]  K. Shinohara,et al.  The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. , 2000, The Journal of urology.

[5]  T. Stamey,et al.  Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. , 2000, The Journal of urology.

[6]  É. Lechevallier,et al.  Effect of digital rectal examination on serum complexed and free prostate-specific antigen and percentage of free prostate-specific antigen. , 1999, Urology.

[7]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[8]  M. Miller,et al.  Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: critical analysis of two different test populations. , 1999, Urology.

[9]  M. Brawer,et al.  Measurement of complexed PSA improves specificity for early detection of prostate cancer. , 1998, Urology.

[10]  W. J. Allard,et al.  Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. , 1998, Clinical chemistry.

[11]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[12]  J. Oesterling,et al.  Update on the appropriate staging evaluation for newly diagnosed prostate cancer. , 1997, The Journal of urology.

[13]  J. Moul,et al.  Age-specific reference ranges for serum prostate-specific antigen in black men. , 1996, The New England journal of medicine.

[14]  J. Oesterling,et al.  Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. , 1996, The Journal of urology.

[15]  H. Klocker,et al.  Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. , 1995, Urology.

[16]  J. Oesterling,et al.  Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. , 1995, The Journal of urology.

[17]  P. Humphrey,et al.  Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. , 1995, The Journal of urology.

[18]  J. Richie,et al.  Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. , 1994, The Journal of urology.

[19]  C G Chute,et al.  Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. , 1993, JAMA.